Molinalogo

Measure

2022

2023

Goal

Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)

65.79%

66.14%

64.90%

Annual Dental Visits (ADV)

40.49%

45.69%

54.60%

Antidepressant Medication Management (AMM) Effective Continuation Phase Treatment

47.25%

66.20%

46.74%

Appropriate Testing for Pharyngitis (CWP)

54.42%

58.85%

77.56%

Appropriate Treatment for Upper Respiratory Infection (URI)

88.38%

88.19%

93.08%

Asthma Medication Ratio (AMR) Total

54.32%

55.51%

69.41%

Avoidance of Antibiotic Treatment for Acute Bronchitis / Bronchiolitis (AAB)

52.23%

51.01%

66.19%

Blood Pressure Control (<140/90) for Patients With Diabetes (BPD)

62.77%

67.64%

68.61%

Breast Cancer Screening (BCS)

51.37%

53.48%

55.25%

Cervical Cancer Screening (CCS)

57.21%

59.37%

59.85%

Childhood Immunization Status (CIS) Combination #10

26.33%

23.84%

35.04%

Chlamydia Screening in Women (CHL) Total

63.67%

64.89%

61.07%

Controlling High Blood Pressure (CBP)

55.96%

63.26%

65.45%

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

80.71%

81.31%

80.86%

Eye Exam for Patients With Diabetes (EED)

57.18%

53.53%

56.20%

Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA) 7-Day Follow-Up Total

NB

NB

27.73%

Follow-Up After Emergency Department Visit for Mental Illness (FUM) 7-Day Follow-Up Total

30.38%

21.97%

46.35%

Follow-Up After Hospitalization for Mental Illness (FUH) 7-Day Follow-Up Total

NB

NB

41.03%

Follow-Up After High-Intensity Care for Substance Use Disorder (FUI) 7-Day Follow-Up Total

NB

NB

37.31%

Follow-Up for Children Prescribed ADHD Medication (ADD) Continuation and Maintenance Phase

57.07%

56.28%

57.90%

Hemoglobin A1c Control for Patients With Diabetes (HBD) HbA1c Control (<8%)

51.82%

50.61%

55.72%

Immunizations for Adolescents (IMA) Combination #2

32.54%

29.88%

38.93%

Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET) Engagement of AOD Treatment Total

NB

NB

16.94%

Kidney Health Evaluation for Patients with Diabetes (KED)

27.91%

29.07%

38.80%

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) Blood Glucose and Cholesterol Testing Total

26.76%

27.33%

39.01%

Pharmacotherapy for Opioid Use Disorder (POD) Total

32.59%

27.07%

31.93%

Pharmacotherapy Management of COPD Exacerbation (PCE) Systemic Corticosteroids

72.66%

70.76%

75.79%

Pharmacotherapy Management of COPD Exacerbation (PCE) Bronchodilator

89.22%

87.58%

86.96%

Plan All-Cause Readmissions (PCR) Observed-to-Expected Ratio 18-64 Years

92.05%

91.45%

≤ 92.72%

Prenatal and Postpartum Care (PPC) Timeliness of Prenatal Care

78.35%

81.02%

86.86%

Prenatal and Postpartum Care (PPC) Postpartum Care

70.07%

71.53%

80.78%

Prenatal Immunization Status (PRS) Combination Rate

15.49%

11.37%

25.81

Risk of Continued Opioid Use (COU) 31-Day Total

12.07%

5.97%

≤ 2.45%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Received Statin Therapy Total

81.84%

81.57%

81.64%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Statin Adherence 80% Total

88.06%

71.96%

73.63%

Statin Therapy for Patients with Diabetes (SPD) Received Statin Therapy

71.53%

69.95%

67.07%

Statin Therapy for Patients with Diabetes (SPD) Statin Adherence 80%

85.03%

69.99%

70.37%

Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) Total

60.89%

64.64%

63.89%

Use of Imaging Studies for Low Back Pain (LBP)

75.76%

76.65%

75.44%

Use of Opioids at High Dosage (HDO)

6.68%

1.40%

≤ 2.19%

Use of Opioids from Multiple Providers (UOP) Multiple Prescribers and Multiple Pharmacies

1.43%

1.34%

≤ 0.87%

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) BMI Percentile

75.67%

78.10%

83.21%